SUZHOU, China and NEW
YORK, May 20, 2019
/PRNewswire/ -- CMAB Biopharma Limited. (CMAB), a strict
"pure-play" contract development and manufacturing organization
(CDMO) focusing solely on services from sequence to commercial
manufacturing for biologic products, has today announced the
appointment of Dr. Wang Yongzhong as
its CEO. He has assumed responsibilities on May 15, and will set the overall enterprise
vision, lead strategic direction and oversee the operations. Dr.
Wang will join the Board of Directors of CMAB.
"On behalf of the Board of Directors, I would like to welcome
Dr. Wang, a highly respected executive in the field. With his deep
expertise of both the industry and markets in which CMAB operates,
we believe he is going to take CMAB to the next level," said Ms.
Mengjiao Jiang, Chairperson of CMAB. "His experience in driving the
innovations at Kanghong Biotech and achieving operation excellence
at Simcere Pharmaceutical Group, his passion for servicing
customers at a global scale, and his authentic team player attitude
make him an extraordinary fit for CMAB." Ms. Jiang added, "We are confident he is the right
person to lead CMAB to the next stage of growth."
Dr. Wang will bring over 20 years of innovation and leadership
experience in global pharmaceutical and biotech industries. He most
recently held a role of President of Pharmaceuticals and EVP at
Simcere, where he oversaw all pilot and commercial manufacturing
operations including a Mab facility and a recombinant protein
facility. He was also responsible for all quality operations
including R&D, production and distribution, supply chain,
engineering, regulatory affairs, and international sales. Among
other duties, he also served as the Chairman of the Board for a
joint venture for therapeutic DNA vaccines and on the joint
steering committee for Simcere's strategic partnership in
biosimilars with AMGEN.
Prior to Simcere, he served as the CEO at Kanghong Biotech,
which successfully developed and launched Conbercept, the first
innovative biological product with an international non-propriety
name from China in 2014. Under his
leadership, Conbercept became the market leader over international
brands in China market in 2016.
Dr. Wang further brought Conbercept to the global stage by clearing
a FDA IND to directly enter phase III clinical trial in the
USA, the first such case for
innovative biological product from China. This achievement was voted as one of
China's Top Ten Advancements in
Pharmaceutical and Biotech Industries in 2016.
Earlier in his career, Dr. Wang worked at Genzyme in
Cambridge, USA. He led CMC and quality projects for
Carticel and Epicel, the first two approved cell therapy products
by the FDA. He was also instrumental for the development and
approval of MACI, the first tissue-engineering product approved by
FDA. He held two patents for MACI, both of which were used for
commercial manufacturing.
Dr. Wang earned his PhD from the Chemical and Biological
Engineering Department at Tufts
University in Boston and
his scientific publications have obtained over 3,000 citations by peers in the biotech
field.
"I'm excited to join the CMAB team," said Dr. Wang. "CMAB has
that rare combination of a customer-oriented philosophy base,
leading technology, amazingly talented people, dedication to
technology innovations, and momentum in the market. I am honored to
join the leadership team and this group of great people that have
fueled CMAB's disruption of the CDMO services. As we add
capabilities for our clients, deepen our enterprise presence, and
expand into the market, our mission remains unchanged – to make our
customers successful in the shortest time possible"
About CMAB:
CMAB is a flexible full-service CDMO
dedicated to providing bespoke development manufacturing services
of antibodies and biologics for clients in China and across the globe. Our adaptable,
service-oriented business enables clients to take their innovative
concepts for tomorrow's medicines from DNA to clinical product
today.
To find out more about our dynamic new CDMO, please go to the
website: www.cmabbio.com
Or contact us:
Email: hello@cmabbio.com
Tel: (86) 0512 67995188
Address: Bld. C37, No. 188 Dong Ping Road, Suzhou Industry
Park,
CMAB Biopharma (Suzhou) Ltd.
View original
content:http://www.prnewswire.com/news-releases/cmab-biopharma-announces-dr-wang-yongzhong-as-ceo-to-strengthen-leadership-and-continue-business-expansion-300853032.html
SOURCE CMAB Biopharma Limited.